BCIQ Profiles

Company Profile Report

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

Kite submits BLA for CD19 CAR T in mantle cell
Kite Pharma Inc. submitted Wednesday a BLA to FDA for KTE-X19 to treat mantle cell lymphoma after reporting Phase II data at the American Society of Hematology meeting showing

Read the full 388 word article

How to gain access

Continue reading with a
two-week free trial.